Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade | Zendy

William Chow | Zendy; Clarissa Amaya | Zendy; Steven Rains | Zendy; Michael Chow | Zendy; Erin B. Dickerson | Zendy; Brad A. Bryan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade

Author(s) -

William Chow,

Clarissa Amaya,

Steven Rains,

Michael Chow,

Erin B. Dickerson,

Brad A. Bryan

Publication year - 2015

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2015.2554

Subject(s) - medicine , angiosarcoma , propranolol , propranolol hydrochloride , scalp , hemangiosarcoma , blockade , radiation therapy , metastasis , oncology , cancer , pathology , surgery , receptor

Patients with stage T2 multilesion angiosarcomas of the scalp and face that are larger than 10 cm demonstrate a 2-year survival rate of 0%. To our knowledge, major therapeutic advances against this disease have not been reported for decades. Preclinical data indicate that blocking β-adrenergic signaling with propranolol hydrochloride disrupts angiosarcoma cell survival and xenograft angiosarcoma progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research